

1 **Title page**

2

3 **Title**

4 Characterization of the Structural and Functional Alteration in Eyes with Diabetic Macular  
5 Ischemia

6

7 **Authors**

8 Wei-Shan Tsai, MD, MSc,<sup>1,2</sup>

9 Sridevi Thottarath, MBBS,<sup>1</sup>

10 Sarega Gurudas, MSc,<sup>2</sup>

11 Elizabeth Pearce, PhD,<sup>3</sup>

12 Andrea Giani, MD,<sup>3</sup>

13 Victor Chong, MD, FRCOphth,<sup>2</sup>

14 Chui Ming Gemmy Cheung, MBBS, FRCOphth,<sup>4</sup>

15 Sobha Sivaprasad, DM, FRCOphth,<sup>1,2</sup>

16

17 **Author Affiliations:**

18 <sup>1</sup> NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation  
19 Trust, London, United Kingdom.

20 <sup>2</sup> Institute of Ophthalmology, University College London, London, United Kingdom.

21 <sup>3</sup> Boehringer Ingelheim, Germany.

22 <sup>4</sup> Singapore Eye Research Institute, Singapore National Eye Centre, Singapore.

23

24 **Correspondence:**

25 Sobha Sivaprasad, FRCOphth, DM; NIHR Moorfields Biomedical Research Centre,  
26 Moorfields Eye Hospital NHS Foundation Trust, 162, City Road, London, EC1V 2PD. E-  
27 mail: sobha.sivaprasad@nhs.net

28

29 **Author Contributions:**

30 Conception and design: Pearce, Giani, Chong, Cheung, Sivaprasad

31 Analysis and interpretation: Tsai, Gurudas, Sivaprasad

32 Data collection: Tsai, Thottarath

33 Obtained funding: Cheung, Sivaprasad

34 Overall responsibility: Tsai, Thottarath, Gurudas, Pearce, Giani, Chong, Cheung, Sivaprasad

35

36 **Meeting Presentation:**

37 This manuscript has not been presented at any conferences or meetings.

38

39 **Financial Support:**

40 The investigator-initiated study was funded by Boehringer Ingelheim, Germany. This study  
41 was supported by the NIHR Biomedical Research Centre at the Moorfields Eye Hospital  
42 National Health Service Foundation Trust and the University College London Institute of  
43 Ophthalmology. W.S.T., S.T., S.G., and S.S. were funded by the ORNATE-India research  
44 project grant (Ref: GCRF UKRI (MR/P027881/1)).

45

46 Boehringer Ingelheim was involved in the design of the study, review, and approval of the  
47 manuscript. The other funders had no role in the design, data management, data analysis,  
48 interpretation, or writing of the manuscript.

49

50

51 **Conflict of Interest:**

52 All authors have completed and submitted the ICMJE disclosure form.

53 The authors have made the following disclosures:

54 S.S. has received financial support from Allergan, Apellis, Bayer, Boehringer Ingelheim,  
55 Novartis, Oxurion, Oculis, and Roche.

56 C.M.G.C. has received financial support made to her institution from Allergan, Bayer,  
57 Boehringer-Ingelheim, Novartis, Roche, Topcon, and Zeiss.

58 E.P. and A.G. are employees of Boehringer-Ingelheim.

59

60 **Human Subjects:**

61 Human subjects were included in this study. The UK National Research Ethics Committee  
62 Service (19/NI/0030) approved the study. The whole research adhered to the tenets of the  
63 Declaration of Helsinki. All patients provided written informed consent.

64

65 No animal subjects were included in this study.

66

67 **Running Head:**

68 DRIL and EZ loss in DMI

69

70 **Address for reprints:**

71 Please refer to the corresponding author.

72

73 **Abbreviations and Acronyms:**

74 **AI** = acircularity index; **BCVA** = best-corrected visual acuity; **CI** = confidence interval;

75 **DCP** = deep capillary plexus; **DME** = diabetic macular edema; **DMI** = diabetic macular

76 ischemia; **DR** = diabetic retinopathy; **DRIL** = disorganization of the retinal inner layers;

77 **DVC** = deep vascular complex; **DVD** = deep vessel density; **ETDRS** = Early Treatment

78 Diabetic Retinopathy Study; **EZ** = ellipsoid zone; **FAZ** = foveal avascular zone; **FD-300** =

79 parafoveal 300- $\mu$ m ring vessel density; **GCL** = ganglion cell layer; **GEE** = generalized

80 estimating equation; **ILM** = internal limiting membrane; **INL** = inner nuclear layer; **IPL** =

81 inner plexiform layer; **LLVA** = low-luminance visual acuity; **OCT** = optical coherence

82 tomography; **OCTA** = optical coherence tomography angiography; **OPL** = outer plexiform

83 layer; **OR** = odds ratio; **PDR** = proliferative diabetic retinopathy; **SCP** = superficial capillary

84 plexus; **SD** = standard deviation; **SVC** = superficial vascular complex; **SVD** = superficial

85 vessel density; **VA** = visual acuity; **VD** = vessel density.

86

87 **Keywords**

88 diabetic macular ischemia; disorganization of the retinal inner layers; ellipsoid zone loss;

89 optical coherence tomography; optical coherence tomography angiography

90

91

92

93

94

95

96

97

98

99

100

101 **Abstract**

102

103 **Objective**

104 To investigate the relative effect of disorganization of the retinal inner layers (DRIL) and  
105 ellipsoid zone (EZ) loss on visual function in diabetic macular ischemia (DMI).

106

107 **Design**

108 Prospective cross-sectional observational study.

109

110 **Participants**

111 Patients with stable treated proliferative diabetic retinopathy (PDR) without center-involved  
112 diabetic macular edema were recruited at the Moorfields Eye Hospital from December 2019  
113 to November 2021. The main inclusion criteria were best-corrected visual acuity (BCVA) of  
114 at least 40 Early Treatment Diabetic Retinopathy Study letters (Snellen equivalent 20/160)  
115 with optical coherence tomography angiography (OCTA) evidence of DMI in at least one  
116 eye.

117

118 **Methods**

119 Each eligible eye of the recruited patients was assessed for BCVA, optical coherence  
120 tomography (OCT) and OCTA metrics. The pre-specified OCT parameters were DRIL and  
121 subfoveal EZ loss. Generalized estimating equations were used.

122

123 **Main Outcomes and Measures**

124 The frequency of DRIL and EZ loss, their relative contributions to vision loss, and their  
125 associations with microvascular alterations were evaluated.

126

127 **Results**

128 There were 125 PDR eyes of 86 patients enrolled. A total of 104 (83%) eyes had BCVA  $\geq$ 70  
129 letters. DRIL was more prevalent than EZ loss (46% [58 eyes] vs. 19% [24 eyes]). On  
130 average, the presence of DRIL had a more pronounced impact on vision, retinal thickness,  
131 and microvascular parameters than EZ loss. After multivariable adjustment, the odds of co-  
132 existing DRIL increased by 12% with every letter decrease in BCVA; however, there was no  
133 statistically significant association of subfoveal EZ loss with BCVA. In eyes with DRIL in  
134 the absence of EZ loss, the BCVA declined significantly by 6.67 letters compared to eyes  
135 with no DRIL nor EZ loss (95% confidence interval [CI],  $-9.92 - -3.41$ ;  $P < 0.001$ ).  
136 However, if DRIL and EZ loss co-existed, the resultant BCVA was 13.22 letters less than  
137 eyes without these structural abnormalities (95% CI,  $-18.85 - -7.59$ ;  $P < 0.001$ ).

138

139 **Conclusions**

140 In DMI patients with Snellen visual acuity of 20/160 or better, eyes with DRIL are associated  
141 with more visual function loss and retinal blood circulation alterations than those with  
142 subfoveal EZ loss only.

143

144

145

146

147

148

149

150

151 **Manuscript**

152 Visual impairment due to diabetic retinopathy (DR) is a growing public health burden.<sup>1</sup> The  
153 most common cause of moderate visual impairment in DR is diabetic macular edema (DME).  
154 However, diabetic macular ischemia (DMI) also contributes to visual acuity (VA) loss but is  
155 less well studied. VA in eyes with angiographic evidence of DMI may range from normal to  
156 severe visual loss. The potential for visual improvement is limited in eyes with severe visual  
157 loss (Snellen 20/200 or worse) due to irreversible macular pathology. Therefore, the  
158 effectiveness of new therapies in macular diseases is mainly evaluated in eyes with VA better  
159 than Snellen 20/200.

160 The prevalence of DMI increases with worsening severity of DR, with the highest  
161 frequency observed in proliferative diabetic retinopathy (PDR). Approximately 77% of the  
162 eyes with PDR have angiographic evidence of DMI as defined by the Early Treatment of  
163 Diabetic Retinopathy Study (ETDRS) criteria.<sup>2,3</sup> Therefore, it is more feasible to study visual  
164 function changes in DMI in eyes with PDR. Eyes with PDR also have the greatest VA  
165 variability compared to other severity levels of DR.<sup>4-6</sup> This heterogeneity may be partly  
166 explained by the presence of DMI.

167 With the advent of optical coherence tomography angiography (OCTA), it is now  
168 possible to better quantify the microvascular changes in DMI and relate them to changes in  
169 visual function. However, these vascular changes may not necessarily cause visual loss  
170 unless associated with neuronal derangement. These neuronal changes may manifest as  
171 disorganization of the retinal inner layers (DRIL) and ellipsoid zone (EZ) loss. Several  
172 reports have shown that these neuronal changes adversely affect visual prognosis.<sup>7,8</sup>  
173 However, their relative contribution to VA loss in PDR eyes with DMI is unclear.

174 Both the presence of DRIL and the length of DRIL have been associated with poor  
175 visual performance.<sup>9-12</sup> In addition, studies on DRIL have shown its association with

176 decreased superficial vessel density (SVD) and deep vessel density (DVD).<sup>13,14</sup> Furthermore,  
177 an enlarged foveal avascular zone (FAZ) area is also inclined to have co-existing DRIL.<sup>15</sup>  
178 However, it is worth knowing that not all eyes with reduced SVD have DRIL.<sup>16</sup>

179       Neuronal changes may also occur in the outer retina in DMI, especially in eyes with  
180 concomitant or previous DME. In retinal diseases, the loss of EZ in the central one millimeter  
181 (mm) subfield on optical coherence tomography (OCT) is a well-established poor visual  
182 prognostic indicator.<sup>11,12,17,18</sup> Both the existence and extent of EZ loss are independent factors  
183 of VA loss in DR.<sup>11,12</sup> Most importantly, investigators have demonstrated that EZ disruption  
184 is more likely to have diminished DVD.<sup>14,19</sup> This finding corresponds to the fact that the  
185 retinal circulation provides 10–15% of the oxygen supply for the photoreceptor layer.<sup>20</sup>  
186 Together, the combination of DRIL and EZ loss may represent a more severe phenotype of  
187 DMI with the worst visual outcome.<sup>21</sup> However, this has not been systematically evaluated.  
188 Moreover, the prevalence of DRIL and EZ loss in PDR eyes with DMI with recoverable VA  
189 has yet to be determined.

190       As microvasculature changes in DMI usually extend beyond the fovea, best-corrected  
191 visual acuity (BCVA) may not be an ideal visual function test as it is a foveal function. Low  
192 luminance visual acuity (LLVA) may provide more information on visual function loss in  
193 DMI because it reflects the function of the post-receptoral pathway in the parafoveal area.<sup>22</sup>

194       Based on these observations, this study aimed to interrogate (1) the prevalence of DRIL  
195 and EZ loss and their linear association with BCVA and LLVA in PDR with Snellen acuity  
196 better than 20/200; (2) the functional and microvascular parameters associated with DRIL  
197 and EZ loss; and (3) the relative contribution of DRIL and EZ loss to VA loss in these eyes.

198

199 **Methods**

200 This prospective cross-sectional observational study was conducted at the Moorfields Eye  
201 Hospital from December 2019 to November 2021. The study adhered to the tenets of the  
202 Declaration of Helsinki and was approved by the United Kingdom National Research Ethics  
203 Committee Service (19/NI/0030). Informed consent was obtained from all eligible  
204 individuals after good explanations.

205 The electronic medical records from January 2019 to December 2019 were reviewed for  
206 patients with stable PDR under follow-up after treatment with panretinal photocoagulation  
207 (PRP), with the last session done at least six months previously. All identified potentially  
208 eligible patients were invited, and those who attended the screening visit were evaluated for  
209 eligibility.

210 Patients were included if they had at least one eye with: (1) stable treated PDR, defined  
211 as no active neovascularization in the past six months following PRP; (2) an enlarged and  
212 irregular FAZ of  $\geq 0.5 \text{ mm}^2$  in the superficial vascular complex (SVC) or parafoveal capillary  
213 dropout in one quadrant or more if the FAZ area was less than  $0.5 \text{ mm}^2$  on OCTA; and (3)  
214 BCVA of at least 40 ETDRS letters (Snellen equivalent 20/160). Both eyes were enrolled if  
215 eligible.

216 The key exclusion criteria were active PDR, defined as neovascularization of the disc  
217 (NVD), neovascularization elsewhere (NVE), and vitreous hemorrhage; the presence of OCT  
218 evidence of center-involved DME; history of intravitreal injection (IVI) in the past six  
219 months; and any condition that, in the investigator's view, could affect VA, such as visually  
220 disabling cataract, epiretinal membrane, or other macular co-morbidities.

### 221 **Visual Acuity Assessment**

222 A masked optometrist assessed the patients' refraction status, BCVA, and LLVA in a  
223 standardized clinic. In brief, the BCVA was obtained using a retro-illuminated high-contrast  
224 ETDRS chart ( $180 \text{ candela/m}^2$ , Precision Vision, Bloomington, IL, USA) at four meters

225 when the room lights were dimmed. The LLVA was examined after placing a neutral density  
226 filter in front of the ETDRS chart without changing the light settings, reducing the luminance  
227 by 2.0 log units.<sup>23</sup> Low-luminance deficiency (LLD) was defined as the letter score of BCVA  
228 minus LLVA.

### 229 **OCT Examination**

230 All patients underwent macular scans centered at the fovea on Spectralis HRA-OCT  
231 (Heidelberg Engineering, Germany). The OCT volume scan was performed on a 20 x 20-  
232 degree cube with 49 raster lines, each containing 1064 pixels, scanned at an interval of 120  
233  $\mu\text{m}$  apart with a speed of 40000 scans/second.<sup>24,25</sup> Only images with a signal strength of  $\geq 20$   
234 dB were used for analysis.

235 A 1,3,6-mm ETDRS grid overlay was placed centered at the foveal depression. The  
236 central subfield thickness (CST) was defined as the average retinal thickness over the central  
237 1-mm diameter circle at the fovea, automatically measured by the inbuilt software. DRIL and  
238 EZ loss were assessed across the seven 1-mm foveal B-scans, including three scans above  
239 and below the central line. Within this 1 x 0.72 mm area, DRIL was judged by the inability to  
240 distinguish the ganglion cell-inner plexiform layer (GCL/IPL) complex, inner nuclear layer  
241 (INL), and outer plexiform layer (OPL) contours,<sup>9,10</sup> and its presence was objectively defined  
242 as the sum of ambiguous boundaries of  $\geq 3500 \mu\text{m}$ . The EZ loss in the same area was  
243 described as a definite break in the EZ after excluding other causes of EZ disruption, such as  
244 a previous macular laser scar. A sum of  $>0 \mu\text{m}$  EZ loss was called EZ loss present. Two  
245 examiners (W.S.T. and S.T.) masked to the associated VA measured the total length of DRIL  
246 and EZ loss. Any discrepancies found were arbitrated by a senior third grader (S.S.).

### 247 **OCTA Acquisition**

248 The device used for acquiring OCTA scans was the Optovue imaging system (Avanti  
249 RTVUE-XR; Fremont, CA, USA, version 2018.0.0.18). It is a spectral-domain OCTA with a

250 light source of 840 nm wavelength. The inbuilt split-spectrum amplitude-decorrelation  
251 angiography (SSADA) technology can produce denoised high-quality scans at a 70000 A-  
252 scans/second speed.<sup>26,27</sup> The device is also equipped with projection artifacts removal and  
253 motion artifacts correction algorithms.<sup>28,29</sup> The software did the FAZ delineation; however,  
254 manual adjustments were made if vessels or suspended scattering particles in motion  
255 (SSPiM) were erroneously included.<sup>30</sup> Segmentation errors, if any, were also manually  
256 rectified.

257 The retinal layers were segmented automatically into two major components by the  
258 inbuilt software- the superficial vascular complex (SVC) and the deep vascular complex  
259 (DVC). The SVC, defined as the slab between the internal limiting membrane (ILM) and 9  
260  $\mu\text{m}$  above the IPL, contains both the nerve fiber layer vascular plexus and the superficial  
261 capillary plexus (SCP). The DVC, starting from 9  $\mu\text{m}$  above the IPL to 9  $\mu\text{m}$  below the OPL,  
262 comprises the intermediate capillary plexus (ICP) and the deep capillary plexus (DCP).

263 Only those images focused on the 3 x 3 mm fovea with a quality score of  $\geq 5$  were  
264 included for OCTA analysis. The readings of the FAZ-associated parameters were collected,  
265 including the FAZ area and the FAZ perimeter. The FAZ acircularity index (AI) was  
266 quantified using the formula defined as the ratio of the measured perimeter to the  
267 circumference of a perfect circle with the same area as the studied FAZ.<sup>31</sup> In addition, the  
268 parafoveal 300- $\mu\text{m}$  ring vessel density (FD-300), indicating the capillary vessel density (VD)  
269 extended 300  $\mu\text{m}$  beyond the FAZ border, was recorded. We also obtained the microvascular  
270 indexes, including SVC VD (SVD) and DVC VD (DVD), from the whole image and  
271 parafoveal region (the ring area between the 1- and 3-mm diameter circle).

## 272 **Statistical Analysis**

273 Demographic, clinical and ocular characteristics were summarized in the whole cohort. As  
274 some subjects were eligible in both eyes, generalized estimating equations (GEE) were used

275 to account for inter-eye correlation, assuming an unstructured correlation structure and robust  
276 standard errors. Univariate and demographic-adjusted analyses using GEE models with the  
277 logit link function for the binary outcomes of DRIL and EZ loss were used to obtain the odds  
278 ratio (OR) of risk factors and their 95% confidence intervals (CI). Age, gender and duration  
279 of diabetes were adjusted for DRIL, while only age was adjusted for EZ loss due to the low  
280 numbers with EZ loss. Univariate and adjusted analyses using GEE models were also used to  
281 obtain the mean difference with 95% CI of risk factors and the interaction effect between the  
282 presence of DRIL and EZ loss for the continuous outcome BCVA. In addition to a priori  
283 confounding demographic variables (age, gender and duration of diabetes), history of  
284 vitrectomy was also adjusted for the outcome of BCVA as it reached statistical significance  
285 in the univariate analysis. Cohen's Kappa was employed to test the intrarater and interrater  
286 reliability.<sup>32</sup> Statistical analysis was performed using the Stata MP version 15.<sup>33</sup> Two-sided *P*  
287 values of 0.05 or lower were considered statistically significant.

288

## 289 **Results**

290 A total of 209 patients with a history of PRP were identified. Among them, 115 patients  
291 attended the screening visit, while the rest refused (*n* = 57) or did not respond (*n* = 37). At  
292 screening, 29 patients failed the eligibility criteria for the following reasons: Poor VA <40  
293 ETDRS letters (*n* = 2), DR severity less than PDR (*n* = 5), active PDR (*n* = 4), center-  
294 involved DME (*n* = 1), not fulfilling the OCTA definition of DMI (*n* = 7), IVI within recent  
295 six months (*n* = 2), visually significant cataract (*n* = 2), severe epiretinal membrane (*n* = 1),  
296 macular scars (*n* = 1), tractional retinal detachment (*n* = 1), neovascular glaucoma (*n* = 2),  
297 and inability to cooperate with the examinations (*n* = 1).

298 Overall, the study recruited 125 eyes of 86 stable treated PDR patients, and 47% were  
299 eligible bilaterally. Fourteen eyes were corrected for FAZ delineation errors, and eight were

300 excluded from OCTA analysis as the quality score was less than five. The average age was  
301  $56.6 \pm 12.6$  years. Baseline demographics and ocular characteristics are summarized in **Table**  
302 **1**. These eyes had a mean BCVA of  $77 \pm 9$  ETDRS letter score, and the majority (83%)  
303 presented with a BCVA of  $\geq 70$  letter score. Their average LLVA was  $66 \pm 12$  letter score.

304 The average FAZ area was  $0.55 \pm 0.39$  mm<sup>2</sup> with a mean FAZ perimeter of  $3.33 \pm 1.39$   
305 mm. The calculated AI was  $1.31 \pm 0.20$ . The total SVD and DVD in the 3 x 3 mm area were  
306  $36.49 \pm 5.30\%$  and  $41.77 \pm 4.86\%$ , respectively. The parafoveal VD highly correlated with  
307 the 3 x 3 mm whole image VD, showing  $38.35 \pm 5.96\%$  and  $43.39 \pm 5.01\%$  in the SVC and  
308 the DVC, respectively. The average FD-300 was  $42.80 \pm 5.01\%$ .

309 Regarding OCT examinations, the average CST was  $263 \pm 42$   $\mu$ m. Approximately half  
310 the eyes had DRIL (46%), and the mean DRIL length was  $3365 \pm 1949$   $\mu$ m. However, only  
311 one-fifth (19%) exhibited EZ loss with a median of 158.5  $\mu$ m (interquartile range from 92.5  
312 to 661.5  $\mu$ m). The intrarater agreement was 100% for DRIL and 76% for EZ loss, and the  
313 interrater agreement was 73% for DRIL and 92% for EZ loss. The results suggested good to  
314 strong intrarater and interrater reliability.

315 The vascular and functional metrics associated with DRIL and subfoveal EZ loss are  
316 summarized in **Tables 2 & 3**. Generally, the presence of DRIL exhibited a more pronounced  
317 influence on all the functional and vascular metrics than the presence of subfoveal EZ loss in  
318 DMI (**Figures 1 and 2**).

319 The univariate analysis showed that a longer duration of diabetes, poorer visual acuity,  
320 larger FAZ parameters (including area, perimeter, and AI), worse OCTA VD (whole image  
321 and parafoveal SVD or DVD), and a thinner CST were associated with DRIL (**Table 2**). The  
322 *P* values remained statistically significant even after demographic adjustment except for the  
323 duration of diabetes. However, age, gender, LLD, previous macular laser, and history of  
324 DME and vitrectomy did not exhibit a definite role in DRIL formation.

325 On the other hand, no specific risk factors were found to be associated with subfoveal  
326 EZ loss in DMI (**Table 3**). Notably, the *P* values for LLD, previous DME, vitrectomy, and  
327 macular laser did not reach statistical significance. Contrary to DRIL, the presence or absence  
328 of subfoveal EZ loss was not significantly altered by the size of FAZ, the length of the  
329 perimeter, the magnitude of AI, the thickness of the central macula, or any VD parameters on  
330 OCTA. The only exception was the BCVA— for every one letter decrease in BCVA, the  
331 odds for EZ loss increased by 6% (OR, 1.06; 95% CI, 1.01–1.11; *P* = 0.03). However, this  
332 significance failed to maintain after age adjustment.

333 At a closer inspection of those influential factors of DRIL after demographic adjustment  
334 (**Table 2**), the odds of having co-existing DRIL increased by 12% with every one letter  
335 decrease in BCVA (OR, 1.12; 95% CI, 1.06–1.18; *P* < 0.001). Moreover, the odds of DRIL  
336 presence increased by 1.42 times per 0.1 mm<sup>2</sup> enlargement in the FAZ area (OR, 1.42; 95%  
337 CI, 1.02–1.99; *P* = 0.04). For example, an eye with a FAZ area of 0.6 mm<sup>2</sup> would be 2.84  
338 times the odds of having DRIL than an eye with a FAZ area of 0.4 mm<sup>2</sup>. Furthermore, the  
339 multivariable analysis showed that the possibility of DRIL presence increased most in the  
340 decline of the whole image DVD among all VD parameters per every 1%-point decrease  
341 (OR, 1.28; 95% CI, 1.15–1.44; *P* < 0.001). Of note, the risk of DRIL was higher with every  
342 1%- point decline in the DVD than in the SVD.

343 **Table 4** illustrates the impact of structural derangement in DMI on different parameters  
344 in more detail by combining the presence (+) or absence (–) of DRIL and EZ loss. Overall,  
345 the presence of DRIL alone was associated with more functional loss (BCVA, LLVA) and  
346 worse OCTA metrics (FAZ area, perimeter, AI, whole image and parafoveal SVD or DVD,  
347 FD-300) than EZ loss alone. The loss of EZ was not significantly associated with the  
348 worsening of any OCTA metrics except the FAZ perimeter and AI. However, concurrent

349 DRIL (+) and EZ loss (+) resulted in the worst performance in almost every item, except the  
350 FAZ area and perimeter.

351 On further examining the relative contribution of DRIL and EZ to visual function after  
352 adjusting for demographic variables and history of vitrectomy (**Table 5**), we discovered that  
353 the presence of DRIL was associated with a decrease in BCVA by 7.68 letters compared to  
354 no DRIL presence (95% CI,  $-10.55 - -4.82$ ;  $P < 0.001$ ) regardless of EZ loss. The influence  
355 of EZ loss was neither remarkable in the unadjusted nor adjusted analysis compared to no EZ  
356 loss. In the presence of DRIL without EZ loss, the BCVA declined by 6.67 letters compared  
357 to eyes with no DRIL and no EZ loss (95% CI,  $-9.92 - -3.41$ ;  $P < 0.001$ ). If DRIL presented  
358 in addition to EZ loss, the BCVA would be lowered by 13.22 letters compared to eyes  
359 without structural abnormalities (95% CI,  $-18.85 - -7.59$ ;  $P < 0.001$ ).

360

## 361 **Discussion**

362 The key findings of our study are: Firstly, approximately 80% of the PDR patients with DMI  
363 in our study cohort had a relatively good BCVA of 70 letters or more, and about half of them  
364 had LLVA of 70 letters or better. Secondly, in these eyes with DMI, DRIL was more  
365 prevalent than EZ loss (46% versus 19%, respectively). Thirdly, DRIL alone was associated  
366 with worse functional and microvascular metrics than those eyes with EZ loss only. Fourth,  
367 concurrent DRIL and EZ loss was present in only 10% of the eyes; however, these eyes had  
368 the worst functional outcomes. Finally, although on average, both the DVD and SVD were  
369 decreased in DRIL, the decrease in DVD was more prevalent.

370 Most patients with OCTA evidence of DMI in this cohort had good visual acuity.

371 Approximately 40% of the eyes with BCVA of 70 letters or more had DRIL. Therefore, the  
372 presence of DRIL may not be a surrogate for severe visual impairment. Considering that  
373 DRIL represents the derangement of the post-photoreceptor pathway, visual acuity may

374 only be affected when the derangement reaches a certain threshold.<sup>9,34</sup> This threshold may  
375 depend both on the duration and quantity of DRIL.

376 In our study, we did not average the DRIL length across the scans but used the total  
377 length of DRIL in each of the seven 1-mm foveal B-scans to obtain the true extent of DRIL.  
378 However, numerous studies have scrutinized the relation between DRIL and VA using  
379 various definitions, and all have observed that, on average, DRIL is associated with VA loss.  
380 For example, DaCosta et al. used multivariable regression analysis in a cross-sectional study  
381 to demonstrate that the horizontal DRIL length was significantly associated with VA ( $P =$   
382  $0.01$ ).<sup>11</sup> Endo et al. further illustrated that the length of DRIL was positively correlated with  
383 the logarithm of the minimum angle of resolution (logMAR) VA.<sup>12</sup> Moreover, DRIL was  
384 proposed as a surrogate predictor of future VA in a longitudinal study by Sun et al., who  
385 reported that an extent of 300  $\mu\text{m}$  DRIL at four months was predictive of 1-line VA loss at  
386 eight months in center-involved DME.<sup>9</sup> The negative influence of DRIL on VA held true in  
387 DME-resolved eyes.<sup>10</sup> We excluded eyes with concomitant DME, but some of these eyes  
388 may have had previous DME. Our study showed that eyes with DRIL had approximately  
389 7.68 letters worse BCVA than non-DRIL eyes regardless of EZ condition. The efficacy of  
390 novel therapeutic agents in preventing visual loss in DMI may be better evaluated in eyes  
391 without DRIL or DRIL with good VA.

392 We also evaluated the relation between the OCTA metrics and DRIL. Importantly, we  
393 observed that an enlarged FAZ area was associated with DRIL. This finding substantiates  
394 observations made in other studies.<sup>15,35</sup> Apart from comparing the average size of the FAZ  
395 area between eyes with and without DRIL, our study specifically pointed out that the odds of  
396 co-existing DRIL increased by 42% with every 0.1  $\text{mm}^2$  increase in the FAZ area (95% CI,  
397 1.02–1.99;  $P = 0.04$ ) after demographic adjustment. However, the cross-sectional research

398 design in all these studies limits inferences about the natural history of DRIL development  
399 and progression.

400 When considering OCTA metrics of VD in DMI, the key observations were a more  
401 profound association of decreased DVD than SVD in eyes with DRIL and a close  
402 relationship between DRIL and AI of 1.5 or more. The relation between DRIL and VD in  
403 different layers is still under debate. Whereas some researchers support that DRIL is  
404 predominantly associated with SVC deficiency,<sup>34,35</sup> others believe that DRIL is also  
405 associated with DVC ischemia besides SVC insufficiency.<sup>14</sup> Our study reinforced the latter  
406 findings by comparing the odds ratios between the two vascular parameters. The  
407 multivariable analysis showed that every 1%-point decrease in SVD increased the chance of  
408 DRIL presence (OR, 1.13; 95% CI, 1.04–1.23;  $P = 0.006$ ), but the same amount of decline in  
409 DVD appeared to have a stronger association with DRIL (OR, 1.28; 95% CI, 1.15–1.44;  $P <$   
410  $0.001$ ). However, the discrepancy may also reflect different DMI phenotypes.

411 Our study did not find a significant role of subfoveal EZ loss alone in visual  
412 performance in DMI with VA better than Snellen 20/200. Sun et al. also reported similar  
413 findings despite a wider visual acuity range (logMAR  $0.28 \pm 0.25$ ). After multivariate  
414 modeling, they reported that the positive correlation between EZ breaks and baseline  
415 logMAR VA became insignificant.<sup>9</sup> We attributed the insignificance in the present study to  
416 the small number of eyes having subfoveal EZ disruption (24 eyes). As countless multivariate  
417 regression analysis studies have demonstrated that EZ loss length contributes to visual  
418 impairment significantly and proportionally,<sup>11,12,17,18</sup> we are convinced that photoreceptor  
419 injury should result in vision loss. However, given the low prevalence of EZ loss in our  
420 study, we inferred that EZ loss might be a late event in DMI,<sup>34</sup> as we showed that eyes with  
421 concurrent DRIL and EZ loss have the worst visual outcome. It may also represent a group

422 with previous DME. However, we could not deduce this from this cohort as only 14% of our  
423 study participants had previous DME.

424 We also showed a synergistic adverse effect of DRIL and EZ loss on vision. The finding  
425 also points to the contribution of DCP changes in DMI as DCP aids in maintaining  
426 photoreceptors. In 2016, Scarinci et al. first described eight DMI eyes with topographic  
427 relation between flow abnormalities in the DCP and attenuated signals in the outer retinal  
428 layers.<sup>36</sup> Following the first publication, Nesper et al. reported quantitative results that a  
429 reduced cone heterogeneity packing index was associated with parafoveal DCP non-  
430 perfusion in ten eyes.<sup>8</sup> In a multivariate linear regression model analyzing sixty-seven  
431 resolved DME, Moon et al. discovered that the recovery of EZ integrity significantly relied  
432 on the baseline DVD.<sup>37</sup> Our study indicated that the DVD loss was not significantly different  
433 between eyes with or without EZ loss. Although it is widely accepted that the DVC  
434 contributes 15% of the oxygen supply to the photoreceptor layer,<sup>38</sup> our study showed that  
435 DVD loss was seen more in DRIL rather than subfoveal EZ loss in DMI. One of the possible  
436 explanations could be that the function of the outer retina is more dependent on the  
437 choroid.<sup>34,38</sup>

438 There are several strengths of this study. To the best of our knowledge, this is the first  
439 observational study that prospectively recruited eyes with DMI in stable treated PDR and  
440 included only eyes with VA better than Snellen 20/200. We also applied stringent OCTA  
441 criteria to define DMI. Moreover, we measured DRIL and EZ loss length across seven scans  
442 within the central 0.72 x 1 mm square zone rather than one cross-sectional scan at the center,  
443 enabling the quantitative data from anatomical structure to reflect the true foveal function  
444 more reliably. We further employed GEE and multivariable statistical models to estimate the  
445 real effect of isolated DRIL and EZ disruption on vision and central microvascular

446 parameters. We believe our findings will offer researchers valuable baseline references for  
447 future studies investigating the natural history of DMI.

448 We also acknowledge some limitations of this study. First, the cross-sectional nature of  
449 this study design inhibited us from predicting the prognosis of DMI. Second, measuring  
450 DRIL and EZ loss length on seven OCT scans can be time-consuming and subject to  
451 detection bias. Third, the conclusions drawn from these pre-selected patients may preclude  
452 the application to non-PDR eyes, although the prevalence of DMI is lower in these eyes.

453 In summary, our study demonstrates that DRIL correlates better with visual acuity loss  
454 than subfoveal EZ disruption in DMI patients with VA better than Snellen 20/200. Many  
455 patients with DRIL still have good visual acuity. In addition, DVD deficiency is more  
456 frequently found than decreased SVD in eyes with DRIL. Finally, concurrent DRIL and EZ  
457 loss is associated with the poorest microvascular supply, and this synergy results in the worst  
458 visual performance.

459

## 460 **Figure Legends**

461 **Figure 1.** The proportion of disorganization of the retinal inner layers (DRIL) in different  
462 characteristics. DRIL was more likely to present in eyes with decreased vision, an enlarged  
463 FAZ area, an elongated FAZ perimeter, a larger AI, a thinner CST, and a worse whole image  
464 SVD and DVD in diabetic macular ischemia.

465

466 Abbreviations: AI = acircularity index; BCVA = best-corrected visual acuity; CST = central  
467 subfield thickness; DRIL = disorganization of the retinal inner layers; DVD = deep vessel  
468 density; FAZ = foveal avascular zone; FD-300 = parafoveal 300- $\mu$ m ring vessel density;  
469 LLVA = low-luminance visual acuity; SVD = superficial vessel density.

470

471 **Figure 2.** The proportion of ellipsoid zone (EZ) loss in different characteristics. EZ loss in  
472 diabetic macular ischemic eyes was only associated with a lower best-corrected visual acuity  
473 (BCVA). However, after multivariate adjustment, the association lost its significance (Table  
474 3). The foveal avascular zone and retinal microvascular parameters were generally  
475 unaffected, contrary to the extensive alteration presented by disorganization of the retinal  
476 inner layers (DRIL).

477

478 Abbreviations: AI = acircularity index; BCVA = best-corrected visual acuity; CST = central  
479 subfield thickness; DRIL = disorganization of the retinal inner layers; DVD = deep vessel  
480 density; EZ = ellipsoid zone; FAZ = foveal avascular zone; FD-300 = parafoveal 300- $\mu$ m  
481 ring vessel density; LLVA = low-luminance visual acuity; SVD = superficial vessel density.

482

#### 483 **Reference**

- 484 1. Steinmetz JD, Bourne RRA, Briant PS, et al. Causes of blindness and vision  
485 impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in  
486 relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease  
487 Study. *The Lancet Global Health*. 2021;9(2):e144-e160. doi:10.1016/S2214-109X(20)30489-7  
488 2. EDTRS. Classification of Diabetic Retinopathy from Fluorescein Angiograms: ETDRS  
489 Report Number 11. *Ophthalmology*. 1991/05/01/ 1991;98(5, Supplement):807-822.  
490 doi:[https://doi.org/10.1016/S0161-6420\(13\)38013-0](https://doi.org/10.1016/S0161-6420(13)38013-0)  
491 3. Sim DA, Keane PA, Zarranz-Ventura J, et al. The Effects of Macular Ischemia on Visual  
492 Acuity in Diabetic Retinopathy. *Investigative Ophthalmology & Visual Science*.  
493 2013;54(3):2353-2360. doi:10.1167/iovs.12-11103  
494 4. Abdelshafy M, Abdelshafy A. Correlations Between Optical Coherence Tomography  
495 Angiography Parameters and the Visual Acuity in Patients with Diabetic Retinopathy. *Clin*.  
496 2020;14:1107-1115. doi:<https://dx.doi.org/10.2147/OPHTH.S248881>  
497 5. Liu L, Jian G, Bao W, et al. Analysis of Foveal Microvascular Abnormalities in Diabetic  
498 Retinopathy Using Optical Coherence Tomography Angiography with Projection Artifact  
499 Removal. *J Ophthalmol*. 2018;2018:3926745-3926745. doi:10.1155/2018/3926745  
500 6. Tsai ASH, Gan ATL, Ting DSW, et al. DIABETIC MACULAR ISCHEMIA: Correlation of  
501 Retinal Vasculature Changes by Optical Coherence Tomography Angiography and Functional  
502 Deficit. *Retina*. Nov 2020;40(11):2184-2190.  
503 doi:<https://dx.doi.org/10.1097/IAE.0000000000002721>  
504 7. Nemiroff J, Kuehlewein L, Rahimy E, et al. Assessing Deep Retinal Capillary Ischemia  
505 in Paracentral Acute Middle Maculopathy by Optical Coherence Tomography Angiography.

506 *American Journal of Ophthalmology*. 2016/02/01/ 2016;162:121-132.e1.  
507 doi:<https://doi.org/10.1016/j.ajo.2015.10.026>

508 8. Nesper PL, Scarinci F, Fawzi AA. Adaptive Optics Reveals Photoreceptor  
509 Abnormalities in Diabetic Macular Ischemia. *PLoS One*. 2017;12(1):e0169926.  
510 doi:10.1371/journal.pone.0169926

511 9. Sun JK, Lin MM, Lammer J, et al. Disorganization of the Retinal Inner Layers as a  
512 Predictor of Visual Acuity in Eyes With Center-Involved Diabetic Macular Edema. *JAMA*  
513 *Ophthalmology*. 2014;132(11):1309-1316. doi:10.1001/jamaophthalmol.2014.2350

514 10. Sun JK, Radwan SH, Soliman AZ, et al. Neural Retinal Disorganization as a Robust  
515 Marker of Visual Acuity in Current and Resolved Diabetic Macular Edema. *Diabetes*.  
516 2015;64(7):2560-2570. doi:10.2337/db14-0782

517 11. DaCosta J, Bhatia D, Talks J. The use of optical coherence tomography angiography  
518 and optical coherence tomography to predict visual acuity in diabetic retinopathy. *Eye*. 05  
519 2020;34(5):942-947. doi:<https://dx.doi.org/10.1038/s41433-019-0606-9>

520 12. Endo H, Kase S, Tanaka H, et al. Factors based on optical coherence tomography  
521 correlated with vision impairment in diabetic patients. *Sci Rep*. 2021;11(1):3004-3004.  
522 doi:10.1038/s41598-021-82334-w

523 13. Onishi AC, Ashraf M, Soetikno BT, Fawzi AA. MULTILEVEL ISCHEMIA IN  
524 DISORGANIZATION OF THE RETINAL INNER LAYERS ON PROJECTION-RESOLVED OPTICAL  
525 COHERENCE TOMOGRAPHY ANGIOGRAPHY. *Retina (Philadelphia, Pa)*. 2019;39(8):1588-  
526 1594. doi:10.1097/IAE.0000000000002179

527 14. Moussa M, Leila M, Bessa AS, et al. Grading of macular perfusion in retinal vein  
528 occlusion using en-face swept-source optical coherence tomography angiography: a  
529 retrospective observational case series. *BMC Ophthalmology*. 2019/06/10 2019;19(1):127.  
530 doi:10.1186/s12886-019-1134-x

531 15. Moein HR, Novais EA, Rebhun CB, et al. Optical Coherence Tomography Angiography  
532 to Detect Macular Capillary Ischemia in Patients with Inner Retinal Changes after Resolved  
533 Diabetic Macular Edema. *Retina*. Dec 2018;38(12):2277-2284.  
534 doi:<https://dx.doi.org/10.1097/IAE.0000000000001902>

535 16. Nicholson L, Ramu J, Triantafyllopoulou I, et al. Diagnostic accuracy of  
536 disorganization of the retinal inner layers in detecting macular capillary non-perfusion in  
537 diabetic retinopathy. *Clin Exp Ophthalmol*. Nov 2015;43(8):735-41. doi:10.1111/ceo.12557

538 17. Lee D-H, Kim JT, Jung D-W, Joe SG, Yoon YH. The Relationship between Foveal  
539 Ischemia and Spectral-Domain Optical Coherence Tomography Findings in Ischemic Diabetic  
540 Macular Edema. *Investigative Ophthalmology & Visual Science*. 2013;54(2):1080-1085.  
541 doi:10.1167/iovs.12-10503

542 18. Balaratnasingam C, Inoue M, Ahn S, et al. Visual Acuity Is Correlated with the Area of  
543 the Foveal Avascular Zone in Diabetic Retinopathy and Retinal Vein Occlusion.  
544 *Ophthalmology*. 2016/11/01/ 2016;123(11):2352-2367.  
545 doi:<https://doi.org/10.1016/j.ophtha.2016.07.008>

546 19. Scarinci F, Nesper PL, Fawzi AA. Deep Retinal Capillary Nonperfusion Is Associated  
547 With Photoreceptor Disruption in Diabetic Macular Ischemia. *Am J Ophthalmol*. Aug  
548 2016;168:129-138. doi:10.1016/j.ajo.2016.05.002

549 20. Birol G, Wang S, Budzynski E, Wangsa-Wirawan ND, Linsenmeier RA. Oxygen  
550 distribution and consumption in the macaque retina. *Am J Physiol Heart Circ Physiol*. Sep  
551 2007;293(3):H1696-704. doi:10.1152/ajpheart.00221.2007

- 552 21. Cheung CMG, Fawzi A, Teo KY, et al. Diabetic macular ischaemia- a new therapeutic  
553 target? *Prog Retin Eye Res.* Dec 11 2021;101033. doi:10.1016/j.preteyeres.2021.101033
- 554 22. Stockman A, Sharpe LT. Into the twilight zone: the complexities of mesopic vision  
555 and luminous efficiency. *Ophthalmic and Physiological Optics.* 2006;26(3):225-239.  
556 doi:<https://doi.org/10.1111/j.1475-1313.2006.00325.x>
- 557 23. Karatsai E, Sen P, Gurudas S, Sivaprasad S. Low Luminance Visual Acuity and Low  
558 Luminance Deficit in Proliferative Diabetic Retinopathy. *Journal of Clinical Medicine.*  
559 2021;10(2):358.
- 560 24. Appukuttan B, Giridhar A, Gopalakrishnan M, Sivaprasad S. Normative spectral  
561 domain optical coherence tomography data on macular and retinal nerve fiber layer  
562 thickness in Indians. *Indian J Ophthalmol.* 2014;62(3):316-321. doi:10.4103/0301-  
563 4738.116466
- 564 25. GmbH HE. SPECTRALIS Imaging Platform Technical Specifications. Accessed 6th Dec,  
565 2021. [https://business-  
566 lounge.heidelbergengineering.com/ve/en/products/spectralis/spectralis/downloads/](https://business-lounge.heidelbergengineering.com/ve/en/products/spectralis/spectralis/downloads/)
- 567 26. Optovue. The New Gold Standard in OCTA Imaging. Updated 2021.  
568 <https://www.optovue.com/products/angiovue>
- 569 27. Jia Y, Tan O, Tokayer J, et al. Split-spectrum amplitude-decorrelation angiography  
570 with optical coherence tomography. *Opt Express.* 2012/02/13 2012;20(4):4710-4725.  
571 doi:10.1364/OE.20.004710
- 572 28. Camino A, Zhang M, Gao SS, et al. Evaluation of artifact reduction in optical  
573 coherence tomography angiography with real-time tracking and motion correction  
574 technology. *Biomed Opt Express.* 2016;7(10):3905-3915. doi:10.1364/BOE.7.003905
- 575 29. Garrity ST, Iafe NA, Phasukkijwatana N, Chen X, Sarraf D. Quantitative Analysis of  
576 Three Distinct Retinal Capillary Plexuses in Healthy Eyes Using Optical Coherence  
577 Tomography Angiography. *Investigative Ophthalmology & Visual Science.* 2017;58(12):5548-  
578 5555. doi:10.1167/iovs.17-22036
- 579 30. Kashani AH, Green KM, Kwon J, et al. Suspended Scattering Particles in Motion: A  
580 Novel Feature of OCT Angiography in Exudative Maculopathies. *Ophthalmology Retina.*  
581 2018/07/01/ 2018;2(7):694-702. doi:<https://doi.org/10.1016/j.oret.2017.11.004>
- 582 31. Yao X, Alam MN, Le D, Toslak D. Quantitative optical coherence tomography  
583 angiography: A review. *Exp Biol Med (Maywood).* Feb 2020;245(4):301-312.  
584 doi:10.1177/1535370219899893
- 585 32. McHugh ML. Interrater reliability: the kappa statistic. *Biochem Med (Zagreb).*  
586 2012;22(3):276-82.
- 587 33. StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX:  
588 StataCorp LLC. [https://www.stata.com/support/faqs/resources/citing-software-  
589 documentation-faqs/](https://www.stata.com/support/faqs/resources/citing-software-documentation-faqs/)
- 590 34. Gemmy Cheung CM, Fawzi A, Teo KYC, et al. Diabetic macular ischaemia- a new  
591 therapeutic target? *Progress in Retinal and Eye Research.* 2021/12/11/ 2021:101033.  
592 doi:<https://doi.org/10.1016/j.preteyeres.2021.101033>
- 593 35. Cennamo G, Montorio D, Fossataro F, Fossataro C, Tranfa F. Evaluation of vessel  
594 density in disorganization of retinal inner layers after resolved diabetic macular edema using  
595 optical coherence tomography angiography. *PLoS One.* 2021;16(1):e0244789.  
596 doi:10.1371/journal.pone.0244789
- 597 36. Scarinci F, Nesper PL, Fawzi AA. Deep Retinal Capillary Nonperfusion Is Associated  
598 With Photoreceptor Disruption in Diabetic Macular Ischemia. Observational Study. *American*

599 *Journal of Ophthalmology*. Aug 2016;168:129-138.  
600 doi:<https://dx.doi.org/10.1016/j.ajo.2016.05.002>  
601 37. Moon BG, Um T, Lee J, Yoon YH. Correlation between Deep Capillary Plexus  
602 Perfusion and Long-Term Photoreceptor Recovery after Diabetic Macular Edema Treatment.  
603 *Ophthalmol Retina*. Mar 2018;2(3):235-243. doi:10.1016/j.oret.2017.07.003  
604 38. Birol G, Wang S, Budzynski E, Wangsa-Wirawan ND, Linsenmeier RA. Oxygen  
605 distribution and consumption in the macaque retina. *American Journal of Physiology-Heart*  
606 *and Circulatory Physiology*. 2007;293(3):H1696-H1704. doi:10.1152/ajpheart.00221.2007  
607